Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

Charles River Laboratories Completes Acquisition of Majority Ownership of Vital River



  Charles River Laboratories Completes Acquisition of Majority Ownership of
  Vital River

Business Wire

WILMINGTON, Mass. -- January 7, 2013

Charles River Laboratories International, Inc. (NYSE:CRL) announced today that
it has completed its acquisition of a 75% ownership of Vital River, the
premier commercial provider of research models and related services in China,
and a licensee of Charles River for the last ten years.

James C. Foster, Chairman, President, and Chief Executive Officer of Charles
River Laboratories, commented, “Through this acquisition, Charles River will
provide high-quality research models and associated services to the emerging
China market for drug discovery and development. We expect demand for research
models in China to significantly increase over the next several years as drug
development initiatives in academia, government and biopharmaceutical
companies expand. Charles River intends to set the standards for research
models in China, the third-largest pharmaceutical market in the world, and
play a leading role in this emerging opportunity.”

As part of the Vital River acquisition, Charles River will be the exclusive
global partner for distribution of model creation services offered through
Beijing Vital Star Biotechnology. The services of Beijing Vital Star
Biotechnology include humanized model creation utilizing inducible pluripotent
stem cell (iPS) and other technologies.

Charles River acquired the 75% ownership of Vital River for approximately $27
million, subject to certain post-closing working capital adjustments. The
transaction is expected to add more than 1% to 2013 total net sales and be
slightly accretive to 2013 earnings per share.

Caution Concerning Forward-Looking Statements

This news release includes forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. Forward-looking
statements may be identified by the use of words such as “anticipate,”
“believe,” “expect,” “will,” “may,” “estimate,” “plan,” “outlook,” and
“project” and other similar expressions that predict or indicate future events
or trends or that are not statements of historical matters. Forward-looking
statements include statements in this press release regarding Charles River’s
expectations with respect to the impact of Vital River on the Company, its
service offerings, net sales and earnings, as well as Charles River’s future
growth in the area of research models and services in China. Forward-looking
statements are based on Charles River’s current expectations and beliefs, and
involve a number of risks and uncertainties that are difficult to predict and
that could cause actual results to differ materially from those stated or
implied by the forward-looking statements. Those risks and uncertainties
include, but are not limited to, the ability to successfully integrate the
acquisition of Vital River. A further description of these risks,
uncertainties, and other matters can be found in the Risk Factors detailed in
Charles River's Annual Report on Form 10-K as filed on February 27, 2012, as
well as other filings we make with the Securities and Exchange Commission.
Because forward-looking statements involve risks and uncertainties, actual
results and events may differ materially from results and events currently
expected by Charles River, and Charles River assumes no obligation and
expressly disclaims any duty to update information contained in this news
release except as required by law.

About Charles River Laboratories

Accelerating Drug Development. Exactly. Charles River provides essential
products and services to help pharmaceutical and biotechnology companies,
government agencies and leading academic institutions around the globe
accelerate their research and drug development efforts. Our dedicated
employees are focused on providing clients with exactly what they need to
improve and expedite the discovery, early-stage development and safe
manufacture of new therapies for the patients who need them. To learn more
about our unique portfolio and breadth of services, visit www.criver.com.

Contact:

Investors:
Charles River Laboratories
Susan E. Hardy, 781-222-6190
Corporate Vice President, Investor Relations
susan.hardy@crl.com
or
Media:
Charles River Laboratories
Amy Cianciaruso, 781-222-6168
Director, Public Relations
amy.cianciaruso@crl.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement